Company: CDT
Filing Date: 2025-02-05
Form Type: S-3
Source: 0001493152-25-005052
Chunk: 20

Company: CDT Equity Inc.
Filing Date: 2025-02-05
Form: S-3
Chunk 20
---
 from accessing those assets for our business and conducting our business as planned. Our business, financial condition, prospects and results of operations could be materially adversely affected as a result of any of these events.

| 11 |

We will require substantial additional funding in the future, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce, or cease our operations.

Our operations have consumed substantial amounts of cash since our inception. As of September 30, 2024, we had an accumulated deficit of $26.7 million and our net loss was $15.5 million for the nine months ended September 30, 2024. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our business will require substantial additional capital for implementation of our long-term business plan and development of clinical assets. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the U.S. As we require additional funds, we may seek to fund our operations through the sale of additional equity securities, debt financing, and/or strategic collaboration agreements. We cannot be sure that additional financing from any of these sources will be available when needed or that, if available, the additional financing will be obtained on favorable terms.

Our future funding requirements will depend on many factors, including, but not limited to:

| ● | the                                                                                                                                
 progress, timing, scope, and costs of our clinical trials, including the ability to timely enroll patients in our potential future 
 clinical trials;                                                                                                                   |
| ● | the                                                                                                                                
 outcome, timing, and cost of regulatory approvals by the FDA and comparable regulatory authorities, including the potential that   
 the FDA or comparable regulatory authorities may require that we perform more studies than those that we currently expect;         |
| ● | the                                                                                                                                
 amount of revenues, if any, from our current clinical assets or any future clinical assets;                                        |
| ● | the                                                                                                                                
 terms and timing of any potential future collaborations, licensing, or other arrangements that we may establish;                   |
| ● | cash                                                                                                                               
 requirements of any future acquisitions and/or the development of other clinical assets;                                           |
| ● | the                                                                                                                                
 costs of operating as a public company;                                                                                            |
| ● | the                                                                                                                                
 time and cost necessary to respond to technological and market developments;                                                       |
| ● | any                                                                                                                                
 disputes which may occur between us,